Pso Far, PsO Good: Bimekizumab (Bimzelx) Shows Long-term Efficacy in Psoriasis
On the heels of its U.S. Food and Drug Administration (FDA) approval for three more inflammatory diseases, bimekizumab-bkzx (Bimzelx, UCB) showed efficacy through four years in psoriasis. Approximately nine out of 10 patients treated with bimekizumab who achieved PASI90 at Year 1, and more than seven out of 10 patients who achieved complete skin clearance […]